NASDAQ$NVCT
Nuvectis Pharma Inc · Q1 2023 earnings
Q1 2023 earnings · · Investor relations
Briefing
NXP900 IND was cleared by the FDA.
Nuvectis Pharma announced that the FDA cleared the Investigational New Drug Application for NXP900, including the Phase 1 clinical trial protocol. Nuvectis now has two precision oncology, clinical-stage drug candidates, NXP800 and NXP900.
- FDA cleared the Company's Investigational New Drug Application for NXP900.
- Nuvectis has two precision oncology, clinical-stage drug candidates, NXP800 and NXP900.
- NXP900 presents a unique opportunity due to its differentiated mechanism of action and pharmacologic attributes.
- Phase 1a study for NXP900 is expected to commence in the coming months.
Headline financials
Revenue & EPS history
Nuvectis Pharma · Revenue · Quarterly
$4.1M
Forward guidance
Nuvectis is focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology and is currently developing two drug candidates, NXP800 and NXP900.
Tailwinds
- NXP800 is a clinical stage, oral small molecule currently in a Phase 1b study.
- NXP800 was granted Fast Track Designation by the FDA for the treatment of platinum-resistant, ARID1a-mutated, ovarian carcinoma.
- NXP900 is a novel inhibitor of SFKs with low nanomolar potency against YES1 and SRC.
- The IND for NXP900 has been cleared by the FDA.
- The Phase 1a study for NXP900 is expected to commence in the coming months.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2023
+2.4%
Avg return
Earnings day
+7.2%
Avg return
5 days after
-3.7%
Avg return
30 days after
65%
13 / 20 earnings
Positive
+29.2%
Q3 2024
Best reaction
-14.9%
Q1 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +9.4% | +31.6% | +8.8% | |
| Q4 2026 | +0.5% | +0.2% | +3.3% | |
| Q3 2025 | -7.9% | -3.5% | +6.1% | |
| Q2 2025 | -5.4% | -17.7% | -10.6% | |
| Q1 2025 | +6.4% | +8.3% | -9.4% | |
| Q4 2024 | -5.8% | -9.1% | +31.1% | |
| Q3 2024 | +29.2% | +71.3% | -24.6% | |
| Q1 2024 | -14.9% | -15.3% | -13.6% | |
| Q4 2023 | -4.5% | -0.4% | -25.1% | |
| Q3 2023 | -7.9% | -6.6% | -8.4% | |
| Q2 2023 | +1.4% | +1.1% | -7.0% | |
| Q1 2023 | +5.8% | +6.3% | +14.0% | |
| Q4 2022 | -7.1% | -9.5% | +9.2% | |
| Q3 2021 | +0.9% | -3.5% | +7.7% | |
| Q3 2022 | +0.9% | -3.5% | +7.7% | |
| Q2 2021 | +1.1% | +10.1% | -0.6% | |
| Q2 2022 | +2.6% | -3.0% | -3.7% | |
| Q1 2021 | +18.8% | +28.8% | -24.4% | |
| Q4 2021 | +18.8% | +33.6% | -15.6% | |
| Q1 2022 | +5.4% | +25.2% | -19.4% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro